network member

Michigan

About Network Member

Currently Enrolling

HCRN-BRE20-468

A Phase II Study of Ribociclib And Endocrine Treatment of Physician’s Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (RaPhLRR Study)

Cancer areas:Breast

Fred & Pamela Buffett Cancer Center

New York University Cancer Institute

Orlando Health Cancer Institute

Parkview Research Center

Penn State Cancer Institute

Providence Cancer Institute

Rutgers Cancer Institute of New Jersey

The Ohio State University

Tufts Medical Center

University of Alabama at Birmingham Comprehensive Cancer Center

University of Arizona Cancer Center

University of Illinois Cancer Center

University of Iowa Holden Comprehensive Cancer Center

University of Michigan Health-West

University of Michigan Rogel Cancer Center

University of Virginia Cancer Center

University of Wisconsin Carbone Cancer Center

Virginia Commonwealth University

See clinicaltrials.gov

Currently Enrolling

HCRN-BRE21-516

BRIDGET: Secondary BRain metastases prevention after Isolated intracranial progression on Trastuzumab/Pertuzumab or T-DM1 in patients with aDvanced human epidermal Growth factor receptor 2+ brEast cancer with the addition of Tucatinib

Cancer areas:Breast

Dana-Farber Cancer Institute

Duke Cancer Institute

MD Anderson Cancer Center

Novant Health Oncology Specialists

Providence Cancer Institute

Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

The Ohio State University

UC San Francisco

University of Michigan Rogel Cancer Center

See clinicaltrials.gov

Enrollment Closed

HCRN-GU19-385

Phase II Trial of Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer (PLANE-PC)

Ulka Vaishampayan

Cancer areas:Prostate

City of Hope

Froedtert & the Medical College of Wisconsin

Knight Cancer Institute at Oregon Health & Science University

University of Michigan Rogel Cancer Center

Winship Cancer Institute of Emory University

See clinicaltrials.gov

Currently Enrolling

HCRN-LUN21-530

MOnaliZumab in Combination With durvAlumab (MEDI4736) Plus Platinum-based chemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer (MOZART)

Cancer areas:Lung

Barbara Ann Karmanos Cancer Center

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

University of Iowa Holden Comprehensive Cancer Center

University of Virginia Cancer Center

See clinicaltrials.gov

Currently Enrolling

HCRN-LYM21-544

Phase 2, open label, multicenter study of pacritinib in relapsed/refractory T-cell lymphoproliferative neoplasms

Cancer areas:Lymphoma

City of Hope

The Ohio State University

University of Michigan Rogel Cancer Center

See clinicaltrials.gov

Currently Enrolling

HCRN-LYM21-546

A phase II study of pembrolizumab and mogamulizumab in advanced-stage, relapsed/refractory cutaneous T-cell lymphomas

Cancer areas:Lymphoma

University of Michigan Rogel Cancer Center

See clinicaltrials.gov

Currently Enrolling

HCRN-LYM22-565

Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma

Cancer areas:Lymphoma

Barbara Ann Karmanos Cancer Center

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

University of Virginia Cancer Center

UT Southwestern Harold C. Simmons Comprehensive Cancer Center

See clinicaltrials.gov

Enrollment Closed

BTCRC-HN17-111

Phase II Trial of Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma: Big Ten Cancer Research Consortium BTCRC-HN17-111

Manish Patel

Cancer areas:Head and Neck

Masonic Cancer Center, University of Minnesota

Robert H. Lurie Comprehensive Cancer Center of Northwestern University

University of Illinois Cancer Center

University of Iowa Holden Comprehensive Cancer Center

University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center

University of Michigan Rogel Cancer Center

University of Wisconsin Carbone Cancer Center

See clinicaltrials.gov

Enrollment Closed

HCRN-LUN21-497

A Phase II Study of GT103 in Combination with Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer

Cancer areas:Lung

Barbara Ann Karmanos Cancer Center

Duke Cancer Institute

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

Summit Health Cancer Center

University of Illinois Cancer Center

University of Virginia Cancer Center

See clinicaltrials.gov

Enrollment Closed

BTCRC-BRE16-042

A Phase II Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients: Big Ten Cancer Research Consortium BTCRC-BRE16-042

Nancy Chan

Cancer areas:Breast

Fred & Pamela Buffett Cancer Center

Michigan State University

New York University Cancer Institute

Rutgers Cancer Institute of New Jersey

University of Wisconsin Carbone Cancer Center

See clinicaltrials.gov